1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH Cancer Center Support Grants (P30) is a grant from the National Institutes of Health (NIH) that funds shared resources and facilities for categorical cancer research conducted by investigators from different disciplines in a multidisciplinary center model.
The P30 core grant supports shared infrastructure integrated with component research projects and program projects within the center, enabling greater productivity than separate projects would achieve alone. Eligible applicants are established cancer research centers at universities, hospitals, and research institutions.
Standard NIH due dates apply, and applications must align with the mission of at least one participating funding organization, including the National Institute of Environmental Health Sciences and the National Institute of Mental Health.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Center Core Grants (P30) | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health To support shared resources and facilities for categorical research by a number of investigators from different disciplines who provide a multidisciplinary approach to a joint research effort or from the same discipline who focus on a common research problem.
The core grant is integrated with the center's component projects or program projects, though funded independently from them. This support, by providing more accessible resources, is expected to assure a greater productivity than from the separate projects and program projects. Use the Explore NIH Grant Opportunities tool to search Grants.
gov. Ready to develop your application? Learn from a step-by-step guide. Standard Due Dates apply.
AIDS and AIDS-Related Applications Beginning with applications for Advisory Council Review in January 2027 (i.e., application due dates on or after May 25, 2026), NIH will no longer accept applications submitted on dedicated AIDS application due dates. ( NOT-OD-26-029 ) Standard Application Due Dates (when applicable) Participating Funding Organizations Each funding opportunity specifies the participating organizations.
Applications must fit within the mission of at least one participating funding organization and meet all opportunity-specific requirements. The following funding organizations participate on at least one active funding opportunity. National Institute of Environmental Health Sciences National Institute of Mental Health For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: Universities, including Rutgers Cancer Institute. Confirm the full requirements in the official notice before applying.
NIH Cancer Center Support Grants (P30) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article